U.S. markets closed
  • S&P Futures

    4,537.75
    -4.00 (-0.09%)
     
  • Dow Futures

    35,511.00
    +31.00 (+0.09%)
     
  • Nasdaq Futures

    15,407.00
    -71.75 (-0.46%)
     
  • Russell 2000 Futures

    2,299.60
    +5.50 (+0.24%)
     
  • Crude Oil

    82.76
    +0.26 (+0.32%)
     
  • Gold

    1,785.80
    +3.90 (+0.22%)
     
  • Silver

    24.25
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1636
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • Vix

    15.01
    -0.48 (-3.10%)
     
  • GBP/USD

    1.3796
    +0.0001 (+0.00%)
     
  • USD/JPY

    114.1600
    +0.1720 (+0.15%)
     
  • BTC-USD

    62,692.08
    -2,327.41 (-3.58%)
     
  • CMC Crypto 200

    1,490.44
    -44.21 (-2.88%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,985.96
    +277.38 (+0.97%)
     

FDA Rebukes Amgen Over Misleading Branding Of Neulasta

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has issued an untitled letter to Amgen Inc (NASDAQ: AMGN) for the misbranding of its blockbuster bone marrow stimulant, Neulasta (pegfilgrastim) injection.

  • Amgen released a promotional communication that makes false or misleading claims and representations about the benefit of Neulasta when administered through the Onpro on-body injector compared to a prefilled syringe (PFS).

  • Amgen used an unvalidated algorithm with unknown performance characteristics and the fact that the study was not balanced or controlled for potential bias, the FDA notes.

  • And while Amgen does note two limitations to the study, the agency adds that the mentions do not mitigate the misleading claims and presentations in the banner.

  • “The above misleading claims and presentations are concerning because they could undermine confidence not just in Neulasta delivered via PFS but also in FDA-licensed biosimilar pegfilgrastim products, which are only delivered via PFS,” the FDA said.

  • Neulasta is the reference product for all FDA-licensed biosimilar pegfilgrastim products, which are only available as a prefilled syringe.

  • Amgen has already been impacted by competition from biosimilars. Q1 2021 Neulasta fell 21% Y/Y to 2 million, as its average U.S. price slipped 30% Y/Y and 9% sequentially.

  • Price Action: AMGN shares are up 0.50% at $245.93 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.